🇺🇸 Emtricitabine (FTC) in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Anaemia — 1 report (10%)
  2. Cd4 Lymphocytes Abnormal — 1 report (10%)
  3. Cd4 Lymphocytes Increased — 1 report (10%)
  4. Cushing^S Syndrome — 1 report (10%)
  5. Deep Vein Thrombosis — 1 report (10%)
  6. Depression — 1 report (10%)
  7. Diabetes Mellitus — 1 report (10%)
  8. Dialysis — 1 report (10%)
  9. Drug Interaction — 1 report (10%)
  10. Drug Resistance — 1 report (10%)

Source database →

Emtricitabine (FTC) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Infectious Disease / Virology approved in United States

Frequently asked questions

Is Emtricitabine (FTC) approved in United States?

Emtricitabine (FTC) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Emtricitabine (FTC) in United States?

National University Hospital, Singapore is the originator. The local marketing authorisation holder may differ — check the official source linked above.